The Global Preterm Birth And Prelabor Rupture Of Membranes (PROM) Testing Market size was USD 1.69 Billion in 2022 and is expected to register a revenue CAGR of 2.8% over the forecast period, according to the latest report by Reports and Data.

Preterm birth is a major cause of infant mortality and morbidity, responsible for over 35% of newborn deaths globally. To address the increasing number of preterm births, healthcare providers are adopting Preterm Birth and PROM Testing, a non-invasive prenatal test that can detect PROM in pregnant women.

The market for non-invasive prenatal diagnostic procedures is also expected to grow due to the rising demand for safer prenatal testing. Non-Invasive Prenatal Testing (NIPT) is a popular prenatal testing method that uses cell-free Deoxyribonucleic Acid (cfDNA) from the mother's blood to detect genetic abnormalities and illnesses in the developing fetus, without the risks associated with invasive testing procedures like amniocentesis. This makes it a preferred choice among pregnant women.

Moreover, the increasing adoption of advanced prenatal diagnostic technologies is driving the growth of the market. With the advancements in technology, newer and better prenatal testing procedures like cfDNA testing and Next-Generation Sequencing (NGS) have been developed, making prenatal testing more accurate and reliable. This has led to a wider application of these technologies in the healthcare sector.

The market for preterm birth and PROM Testing is experiencing growth due to a rise in demand from different end-use sectors such as hospitals, diagnostic labs, and research institutions. This has resulted in increased revenue for the market. For instance, Mayo Clinic and Natera, a well-known company providing genetic testing and diagnostics, have partnered to create and market innovative non-invasive prenatal tests for the early identification of preterm birth and other pregnancy-related conditions in 2020.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/6018

Some of the prominent players profiled in the global preterm birth and PROM testing market include Abbott Laboratories, Alere Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics, Sera Prognostics, Inc., Cooper Surgical, Inc., Quidel Corporation, and NanoEntek.

Some Key Highlights from the Report

• The global market for testing preterm birth and premature rupture of membranes (PROM) is expected to see significant revenue growth in the coming years, with the foetal fibronectin test projected to be the main contributor. This is due to the rising incidence of preterm birth, and the need for accurate and effective diagnostic tools. The foetal fibronectin test, which detects a protein produced by foetal membranes that indicates preterm delivery, is widely used for diagnosing preterm labour and PROM.
• The 23-week segment is expected to generate a significant portion of revenue in the global market for preterm birth and PROM testing over the forecast period. This is because newborns born extremely prematurely have a high mortality rate, with less than 5% surviving if born before 23 weeks, according to the Centers for Disease Control and Prevention (CDC). Therefore, it is crucial to diagnose and treat preterm birth and PROM at an early stage in this particular population.
• The North American market is expected to have the largest revenue share in the global market for preterm birth and PROM testing, as a result of rising rates of premature births. In the United States, approximately 10% of all live births are classified as preterm, according to the Centers for Disease Control and Prevention (CDC).
• On March 3, 2021, Cooper Surgical, Inc. acquired the prenatal and perinatal products division of Safe Obstetric Systems, a company that manufactures medical devices. This acquisition will broaden Cooper Surgical's portfolio of products in the field of obstetrics and gynecology.
• On June 26, 2020, LabCorp introduced the Panorama Test, a non-invasive prenatal test. The test detects chromosomal abnormalities using cell-free DNA technology and is suited for use in high-risk pregnancies.

To understand how our Preterm Birth and Prelabor Rupture of Membranes (PROM) Testing Market can bring difference to your business strategy:-https://www.reportsanddata.com/download-summary-form/6018

For the purpose of this report, Reports and Data has segmented the global preterm birth and PROM testing market on the basis of Product Type Outlook, Test Type Outlook, Gestational Age Outlook, End-use Outlook, and Regional Outlook:

Product Type Outlook (Revenue, USD Billion; 2022 - 2032)

• Instruments
• Consumables
• Services

Test Type Outlook (Revenue, USD Billion; 2022 - 2032)

• Fetal Fibronectin Test
• Ureaplasma Testing
• Others

Gestational Age Outlook (Revenue, USD Billion; 2022 - 2032)

• 23 weeks
• 23-33 weeks
• 33 weeks

End-use Outlook (Revenue, USD Billion; 2022 - 2032)

• Hospitals
• Clinics
• Diagnostic Laboratories

Regional Outlook (Revenue, USD Billion; 2022-2032)

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East Africa

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/6018

Key Advantages of Preterm Birth and Prelabor Rupture of Membranes (PROM) Testing Report:

• Identification and analysis of the market size and competition
• Qualitative and quantitative analysis of the market data
• Data validated by industry experts after extensive primary and secondary research
• Extensive regional analysis of the Preterm Birth and Prelabor Rupture of Membranes (PROM) Testing industry
• Profiling of key players along with their business overview,  business strategies, deals and partnerships, and product portfolio
• SWOT and Porter’s Five Forces Analysis for in-depth understanding of the competitive landscape
• Feasibility analysis and investment analysis to enable strategic investment decisions
• Analysis of opportunities, drivers, restraints, challenges, risks, and limitations

Conclusively, all aspects of the Preterm Birth and Prelabor Rupture of Membranes (PROM) Testing market are quantitatively as well qualitatively assessed to study the global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.